SCLP Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Scancell Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.095 |
| 52 Week High | UK£0.20 |
| 52 Week Low | UK£0.073 |
| Beta | -0.094 |
| 1 Month Change | -11.63% |
| 3 Month Change | 12.43% |
| 1 Year Change | -5.94% |
| 3 Year Change | -25.49% |
| 5 Year Change | 68.14% |
| Change since IPO | 211.48% |
Recent News & Updates
Shareholder Returns
| SCLP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -5.0% | 3.4% | -0.2% |
| 1Y | -5.9% | -12.8% | 3.3% |
Return vs Industry: SCLP exceeded the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: SCLP underperformed the UK Market which returned 4% over the past year.
Price Volatility
| SCLP volatility | |
|---|---|
| SCLP Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 3.4% |
Stable Share Price: SCLP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SCLP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 61 | Phillip L’Huillier | www.scancell.co.uk |
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, melanoma, ovarian, lung, and pancreatic cancers; and Modi-2, which targets homocitrullinated cancer antigens.
Scancell Holdings plc Fundamentals Summary
| SCLP fundamental statistics | |
|---|---|
| Market cap | UK£97.59m |
| Earnings (TTM) | -UK£15.81m |
| Revenue (TTM) | n/a |
Is SCLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCLP income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£15.81m |
| Earnings | -UK£15.81m |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -95.8% |
How did SCLP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 12:49 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scancell Holdings plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Julie Simmonds | Panmure Liberum |
| Julie Simmonds | Panmure Liberum |